BiotechTube

DFN-15

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine With Aura

Conditions

Migraine With Aura, Migraine Without Aura, Allodynia

Trial Timeline

May 9, 2018 → Apr 12, 2019

NCT ID
NCT03472378

About DFN-15

DFN-15 is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Migraine With Aura. The current trial status is completed. This product is registered under clinical trial identifier NCT03472378. Target conditions include Migraine With Aura, Migraine Without Aura, Allodynia.

What happened to similar drugs?

20 of 20 similar drugs in Migraine With Aura were approved

Approved (20) Terminated (1) Active (0)
✅Galcanezumab + ErenumabEli LillyApproved
✅Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
✅Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
✅tramadol HCl/acetaminophenJohnson & JohnsonApproved
✅topiramate; almotriptan malateJohnson & JohnsonApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mgAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03472378Phase 2Completed

Competing Products

20 competing products in Migraine With Aura

See all competitors
ProductCompanyStageHype Score
DFN-11Dr. Reddy's LaboratoriesPhase 2
32
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed)Dr. Reddy's LaboratoriesPhase 1
26
DFN-11Dr. Reddy's LaboratoriesPhase 3
37
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B)Dr. Reddy's LaboratoriesPhase 2
32
ABP-450AEON BiopharmaPhase 2
17
Lasmiditan + PlaceboEli LillyPhase 3
40
Placebo + LY2300559Eli LillyPhase 2
27
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
29
ABP-450 + PlaceboAEON BiopharmaPhase 2
25
Lasmiditan + PlaceboEli LillyPhase 2
35
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Galcanezumab + ErenumabEli LillyApproved
43
Aricept (donepezil hydrochloride)EisaiPhase 2
35
E2007EisaiPhase 2
35
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
43
Galcanezumab + PlaceboEli LillyPhase 3
40
Lasmiditan + PlaceboEli LillyPhase 2
35
Galcanezumab + PlaceboEli LillyPhase 3
40